Hansoh Pharmaceutical Group Company Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Hansoh Pharmaceutical Group Company Limited's yearly results (2022–2025), compared with companies in China. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Debt due within a year is covered 166.4 times by its yearly operating cash. Higher than 97% of companies in China.
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 10.0 times. Higher than 93% of companies in China.
- Profit Cash Ratio: Over the last 3 years, every ¥100 of reported profit came with ¥104 of operating cash. Lower than 92% of companies in China.
Where ¥100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
¥104Over the last 3 years, every ¥100 of reported profit came with ¥104 of operating cash.
Lower than 92% of companies in China.
Self-Funding Ratio
10.0×Over the last 3 years its own operating cash covered its investment spending (capex) 10.0 times.
Higher than 93% of companies in China.
Cash Locked Ratio
¥14For every ¥100 of sales, ¥14 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ¥32 tied up three years earlier.
More money tied up than 83% of companies in China.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 86% of companies in China.
Growth Efficiency Ratio
¥53Sales grew 60% in 3 years; of every extra ¥100 of sales, ¥53 became extra profit.
Higher than 91% of companies in China.
Asset Productivity Ratio
+60% / +33%In 3 years sales changed by +60% while total assets changed by +33%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
166.4×Debt due within a year is covered 166.4 times by its yearly operating cash.
Higher than 97% of companies in China.
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
99%Of every ¥100 the company owns, ¥99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 72% of companies in China.
Tangible Net Worth Ratio
99%Of every ¥100 of net worth, ¥99 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 90% of companies in China.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Hansoh Pharmaceutical Group Company Limited owes ¥0.11 for every ¥1 it owns. Net profit rose 27% in the year to Dec 2025, and grew 29% a year on average over 3 years.
Compared with companies in China · latest annual results Dec 2025.
P/E ratio
25.9Investors pay ¥25.9 for every ¥1 of Hansoh Pharmaceutical Group Company Limited's yearly profit, higher than 87% of companies in China.
P/B ratio
4.65The share price is 4.65 times Hansoh Pharmaceutical Group Company Limited's book value per share, higher than 90% of companies in China.
Market cap
HK$193.2 BThe total market value of all of Hansoh Pharmaceutical Group Company Limited's shares at today's price (share price × number of shares), larger than 52% of companies in China. PosiCap size class: Tito Cap.
Net worth (book value)
¥35.4 BWhat Hansoh Pharmaceutical Group Company Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Dec 2025).
Return on equity (ROE)
19.4%Hansoh Pharmaceutical Group Company Limited earned 19.4% on its shareholders' money over the last year, higher than 66% of companies in China.
Owes vs Owns
0.11×Hansoh Pharmaceutical Group Company Limited owes ¥0.11 for every ¥1 it owns (low), lower than almost all companies in China.
Dividend yield
1.41%Hansoh Pharmaceutical Group Company Limited pays 1.41% of its share price as dividends a year, lower than 83% of dividend-paying companies in China.
Revenue growth
+23%Revenue rose 23% in the year to Dec 2025, and grew 17% a year on average over 3 years.
Profit growth
+27%Net profit rose 27% in the year to Dec 2025, and grew 29% a year on average over 3 years.
Profit margin
37.0%Hansoh Pharmaceutical Group Company Limited keeps ¥37 of every ¥100 of revenue as net profit.
Cash quality
1.2×Cash from Hansoh Pharmaceutical Group Company Limited's business was 1.2× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
1754.3×Hansoh Pharmaceutical Group Company Limited's operating profit covered its interest costs 1754.3 times in the year to Dec 2025.
Cash vs debt
Net cashHansoh Pharmaceutical Group Company Limited held ¥31.5 B more cash than debt (net cash) at Dec 2025.
Questions
What is Hansoh Pharmaceutical Group Company Limited's P/E ratio?
Investors pay ¥25.9 for every ¥1 of Hansoh Pharmaceutical Group Company Limited's yearly profit, higher than 87% of companies in China.
What is Hansoh Pharmaceutical Group Company Limited's return on equity?
Hansoh Pharmaceutical Group Company Limited earned 19.4% on its shareholders' money over the last year, higher than 66% of companies in China.
How much does Hansoh Pharmaceutical Group Company Limited owe compared with what it owns?
Hansoh Pharmaceutical Group Company Limited owes ¥0.11 for every ¥1 it owns (low), lower than almost all companies in China.
Does Hansoh Pharmaceutical Group Company Limited pay a dividend?
Yes. Hansoh Pharmaceutical Group Company Limited pays 1.41% of its share price as dividends a year, lower than 83% of dividend-paying companies in China.
Is Hansoh Pharmaceutical Group Company Limited's revenue growing?
Revenue rose 23% in the year to Dec 2025, and grew 17% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.